Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Cytotherapy|May 16, 2019
Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donorsLaura F Newell, Kelsea M Shoop, Rebekah J Knight, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 12, 2015
Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802Shernan G Holtan, Michael R Verneris, Kirk R Schultz, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 7, 2021
Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutationsLaura F Newell, Jennifer Dunlap, Ken Gatter, et al.
Blood Advances|November 28, 2022
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemiaCurtis A Lachowiez, Nicola Long, Jennifer Saultz, et al.
Cytotherapy|January 23, 2023
Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse ratesGeorgeann Booth, Yun Yu, Rogelyn P Harlan, et al.
Transplantation and Cellular Therapy|April 26, 2021
Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or RelapseLaura F Newell, Todd Williams, James Liu, et al.
American Journal of Hematology|November 18, 2015
Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanismMichael R Garbati, Catherine A Welgan, Sally H Landefeld, et al.
The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Cancers|June 12, 2026
Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot StudyLaura F Newell, Eric Twohey, Jason Sweetnam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.
Pageof 4